Bright Minds Biosciencesannounces participation in the upcoming scientific conferences and partnering events

Press Release

Bright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202 Bright Minds Biosciences will participate in BIO Europe partnering event and Chicago Biocapital Summit to present its innovation in neuroscience NEW YORK, October 3, 2024 Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly…

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Press Release

Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist. Its G-protein biased agonismprovides an improved mechanism of action for chronic dosing Financial runway extending into 2026 enabling key data readout Conference call& KOL Event…